Pseudomonas aeruginosa: Infections and novel approaches to treatment "Knowing the enemy " the threat of Pseudomonas aeruginosa and exploring novel approaches to treatment

被引:43
|
作者
Sathe, Nikhil [1 ,2 ]
Beech, Peter [2 ]
Croft, Larry [2 ]
Suphioglu, Cenk [3 ]
Kapat, Arnab [1 ]
Athan, Eugene [4 ]
机构
[1] Reliance Life Sci Pvt Ltd, Dhirubhai Ambani Life Sci Ctr, Thane Belapur Rd, Navi Mumbai 400701, India
[2] Deakin Univ, Sch Life & Environm Sci, Melbourne Burwood Campus,221 Burwood Highway, Burwood, Vic 3125, Australia
[3] Deakin Univ, Sch Life & Environm Sci, NeuroAllergy Res Lab, Geelong Campus Waurn Ponds,75 Pigdons Rd, Waurn Ponds, Vic 3216, Australia
[4] Deakin Univ, Sch Med, POB 281, Geelong, 3220, Australia
来源
INFECTIOUS MEDICINE | 2023年 / 2卷 / 03期
关键词
Pseudomonas; Infections; Antibiotics; Resistance; Novel Approaches; Bacteriophages; Immunotherapy; Vaccines; URINARY-TRACT-INFECTION; VENTILATOR-ASSOCIATED PNEUMONIA; QUORUM-SENSING INHIBITORS; SUPPURATIVE OTITIS-MEDIA; CYSTIC-FIBROSIS PATIENTS; MULTIDRUG-RESISTANT; BIOFILM FORMATION; RISK-FACTORS; NOSOCOMIAL INFECTIONS; ANTIMICROBIAL RESISTANCE;
D O I
10.1016/j.imj.2023.05.003
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Pseudomonas aeruginosa is an aerobic Gram-negative rod-shaped bacterium with a comparatively large genome and an impressive genetic capability allowing it to grow in a variety of environments and tolerate a wide range of physical conditions. This biological flexibility enables the P. aeruginosa to cause a broad range of infections in patients with serious underlying medical conditions, and to be a principal cause of health care associated infection worldwide. The clinical manifestations of P. aeruginosa include mostly health care associated infections and community-acquired infections. P. aeruginosa possesses an array of virulence factors that counteract host defence mechanisms. It can directly damage host tissue while utilizing high levels of intrinsic and acquired antimicrobial resistance mechanisms to counter most classes of antibiotics. P. aeruginosa co-regulates multiple resistance mechanisms by perpetually moving targets poses a significant therapeutic challenge. Thus, there is an urgent need for novel approaches in the development of anti- Pseudomonas agents. Here we review the principal infections caused by P. aeruginosa and we discuss novel therapeutic options to tackle antibiotic resistance and treatment of P. aeruginosa infections that may be further developed for clinical practice.
引用
收藏
页码:178 / 194
页数:17
相关论文
共 50 条
  • [31] Influential Factors in the Treatment of Pseudomonas aeruginosa Infections at a Tertiary Hospital in Vietnam
    Nguyen, Tiep Khac
    Le, Ngoc Khanh
    Nhung, Pham Hong
    Bui, Thao Thi Huong
    Wang, Gang
    Bambeke, Francoise Van
    Huong, Phung Thanh
    MICROBIAL DRUG RESISTANCE, 2025, 31 (02) : 27 - 33
  • [32] Treatment of carbapenem-resistant Pseudomonas aeruginosa infections: a case for cefiderocol
    Canton, Rafael
    Doi, Yohei
    Simner, Patricia J.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2022, 20 (08) : 1077 - 1094
  • [33] Annexin II is a novel receptor for Pseudomonas aeruginosa
    Kirschnek, S
    Adams, C
    Gulbins, E
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 327 (03) : 900 - 906
  • [34] Pseudomonas Aeruginosa Lectins As Targets for Novel Antibacterials
    Grishin, A. V.
    Krivozubov, M. S.
    Karyagina, A. S.
    Gintsburg, A. L.
    ACTA NATURAE, 2015, 7 (02): : 29 - 41
  • [35] Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa
    Corbella, Laura
    Boan, Jorge
    San-Juan, Rafael
    Fernandez-Ruiz, Mario
    Carretero, Octavio
    Lora, David
    Hernandez-Jimenez, Pilar
    Ruiz-Ruigomez, Maria
    Rodriguez-Goncer, Isabel
    Tiago Silva, Jose
    Lopez-Medrano, Francisco
    Lizasoain, Manuel
    Villa, Jennifer
    Manuel Caro-Teller, Jose
    Aguado, Jose M.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2022, 59 (02)
  • [36] Innovative Approaches to Suppressing Pseudomonas aeruginosa Growth and Virulence: Current Status and Future Directions
    Patil, Sandip
    Chen, Xiaowen
    Wen, Feiqiu
    CELLULAR MICROBIOLOGY, 2024, 2024
  • [37] Development of a novel hybrid antimicrobial peptide for targeted killing of Pseudomonas aeruginosa
    Kim, Hyun
    Jang, Ju Hye
    Kim, Sun Chang
    Cho, Ju Hyun
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 185
  • [38] Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa:: Epidemiology and treatment options
    Obritsch, MD
    Fish, DN
    MacLaren, R
    Jung, R
    PHARMACOTHERAPY, 2005, 25 (10): : 1353 - 1364
  • [39] Pseudomonas aeruginosa biofilm infections: From molecular biofilm biology to new treatment possibilities
    Tolker-Nielsen, Tim
    APMIS, 2014, 122 : 1 - 51
  • [40] Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience
    Bassetti, Matteo
    Castaldo, Nadia
    Cattelan, Annamaria
    Mussini, Cristina
    Righi, Elda
    Tascini, Carlo
    Menichetti, Francesco
    Mastroianni, Claudio Maria
    Tumbarello, Mario
    Grossi, Paolo
    Artioli, Stefania
    Carannante, Novella
    Cipriani, Ludovica
    Coletto, Davide
    Russo, Alessandro
    Digaetano, Margherita
    Losito, Angela Raffaella
    Peghin, Maddalena
    Capone, Alessandro
    Nicole, Stefano
    Vena, Antonio
    Pecori, Davide
    Carnellutti, Alessia
    Givone, Filippo
    Graziano, Elena
    Merelli, Maria
    Cadeo, Barbara
    Verdenelli, Stefano
    Fabiani, Silvia
    Gianluca, Russo
    Oliva, Alessandra
    Ciardi, Maria Rosa
    Ajassa, Camilla
    Tieghi, Tiziana
    Tumbarello, Mario
    Raffaelli, Francesca
    Rovelli, Cristina
    Caruana, Giorgia
    Luzzati, Roberto
    Bontempo, Giulia
    Petrosillo, Nicola
    Rizzardini, Giuliano
    Coen, Massimo
    Passerini, Matteo
    Mastroianni, Antonio
    Urso, Filippo
    Bianco, Maria Francesca
    Borgia, Guglielmo
    Gentile, Ivan
    Maraolo, Alberto Enrico
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2019, 53 (04) : 408 - 415